Replimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlight

from BioSpace · host BioSpace

After two rejections, Replimune has made it across the regulatory finish line with its twice-rejected therapy for advanced melanoma. Meanwhile, the last of the major pharmas, including Eli Lilly and Novo Nordisk, reported second quarter earnings, and psychedelics made headlines once again.

Episode metadata supplied by the publisher feed · Published Aug 12, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

Replimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlight

0:00 19:01

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of BioSpace?

This episode is 19 minutes long.

When was this BioSpace episode published?

This episode was published on August 12, 2026.

Can I download this BioSpace episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!